Kindred Biosciences, Inc. (KIN): Price and Financial Metrics

Kindred Biosciences, Inc. (KIN)

Today's Latest Price: $4.09 USD

0.22 (5.68%)

Updated Jul 8 4:00pm

Add KIN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

KIN Stock Summary

  • With a price/sales ratio of 36.54, Kindred Biosciences Inc has a higher such ratio than 95.23% of stocks in our set.
  • With a year-over-year growth in debt of 1,145.79%, Kindred Biosciences Inc's debt growth rate surpasses 98.21% of about US stocks.
  • As for revenue growth, note that KIN's revenue has grown 75.09% over the past 12 months; that beats the revenue growth of 92.69% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Kindred Biosciences Inc, a group of peers worth examining would be PSNL, MRAM, JG, CERS, and PACB.
  • Visit KIN's SEC page to see the company's official filings. To visit the company's web site, go to
KIN Daily Price Range
KIN 52-Week Price Range

KIN Stock Price Chart Technical Analysis Charts

KIN Price/Volume Stats

Current price $4.09 52-week high $11.93
Prev. close $3.87 52-week low $3.11
Day low $3.78 Volume 212,246
Day high $4.10 Avg. volume 308,595
50-day MA $4.62 Dividend yield N/A
200-day MA $6.86 Market Cap 160.70M

Kindred Biosciences, Inc. (KIN) Company Bio

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company was founded in 2012 and is based in Burlingame, California.

KIN Latest News Stream

Event/TimeNews Detail
Loading, please wait...

KIN Latest Social Stream

Loading social stream, please wait...

View Full KIN Social Stream

Latest KIN News From Around the Web

Below are the latest news stories about Kindred Biosciences Inc that investors may wish to consider to help them evaluate KIN as an investment opportunity.

Is the Options Market Predicting a Spike in Kindred Biosciences (KIN) Stock?

Investors need to pay close attention to Kindred Biosciences (KIN) stock based on the movements in the options market lately.

Yahoo | June 29, 2020

It’s Showtime for This European Cinema Chain’s Stock

Cinema chains will have to reckon with smaller audiences after the pandemic. Kinepolis is in a better position than most—it owns 53 of its sites and invested early in wider seats that are set apart.

Yahoo | June 19, 2020

Hedge Funds Cautiously Watching Kindred Biosciences Inc (KIN)

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]

Yahoo | June 15, 2020

Kindred Bio to downsize in cost-cutting move

Aimed at reducing operating expenses, Kindred Biosciences (KIN) will focus its resources on late-stage assets, prioritizing its IL-31 antibody, IL4 receptor antibody and parvovirus antibody programs, and will cut ~25 employees, including President, COO and co-founder Denise Bevers (she will remain on the board).The actions should trim ~$10M in operating...

Seeking Alpha | June 8, 2020

Kindred Biosciences Announces Plan to Strengthen its Strategic Position

Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced a plan to enhance its strategic position. The company will prioritize its most attractive late stage programs and substantially reduce expenses to best position it for success with the previously announced business model.

Yahoo | June 8, 2020

Read More 'KIN' Stories Here

KIN Price Returns

1-mo -17.87%
3-mo -1.21%
6-mo -58.89%
1-year -49.32%
3-year -52.44%
5-year -39.05%
YTD -51.77%
2019 -22.56%
2018 15.87%
2017 122.35%
2016 25.00%
2015 -54.36%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9501 seconds.